Mumbai: Glenmark Pharmaceuticals Ltd (Glenmark), a research-led, global pharmaceutical company, announced the launch of GLIPIQⓇ (semaglutide) in India for the management of Type 2 Diabetes Mellitus (T2DM) on Saturday, setting a new benchmark in affordability for GLP-1 therapy and expanding access to advanced diabetes treatment for patients.
For many patients, the decision to start advanced injectable therapy is often delayed due to cost and complexity. By significantly improving affordability, GLIPIQⓇ aims to expand access to GLP-1 therapy and enable earlier treatment initiation across a broader patient population.
GLIPIQⓇ is available in both vial and pre-filled pen formulations. The product has been approved by the Central Drugs Standard Control Organization (CDSCO) following a multicentre, randomised, comparative, active-controlled, open-label Phase III clinical study conducted in India, demonstrating favourable efficacy and safety outcomes in Indian patients with Type 2 diabetes.
At the core of GLIPIQⓇ is its vial-based formulation with dose-specific syringes, designed to enable a more accessible, flexible, and clinically manageable approach to GLP-1 therapy. The vial formulation supports physician-guided dosing aligned to patient needs, particularly in the early stages of treatment.
It also offers a cost-effective treatment pathway, helping expand access to therapy and treatment adherence. The expected weekly cost of treatment with GLIPIQⓇ vials range from ₹325 to ₹440, significantly lowering the cost barrier to initiate GLP-1 therapy in India and establishing a more affordable entry point into this class of treatment.
In addition to vials, GLIPIQⓇ is also available in pre-filled pen format, offering convenience of self dosing for long-term therapy. Together, the two formats – vial and pen – enable a structured treatment pathway. This approach supports continuity of care, improved adherence, and sustained treatment outcomes. Both presentations are available in strengths of 2 mg/1.5 mL, 4 mg/3 mL, and 8 mg/3 mL.
Glenmark is also introducing ‘Sankalp’, a patient support program (PSP) designed to support therapy initiations, improve comfort with injectable treatment, and enable long-term adherence. This reflects Glenmark’s commitment to not just improving affordability but enabling patients to stay on therapy and achieve better health outcomes.
Alok Malik, President and Business Head, India Formulations, Glenmark Pharmaceuticals Ltd., said, “Affordability is one of the biggest barriers to initiating advanced diabetes therapy in India. With GLIPIQⓇ, we are setting a new benchmark in affordability for GLP-1 therapy, with weekly treatment starting at ₹325. The vial-based format enables us to offer a more affordable option while supporting clinically guided initiation and flexible dosing.
Building on our experience in the GLP-1 category, including Lirafit™ (Liraglutide), and supported by our ‘Sankalp’ program, we aim to help more patients access, initiate, and continue therapy over time.”
Semaglutide is a GLP-1 receptor agonist widely used in the management of Type 2 Diabetes patients particularly with comorbidities like obesity, established atherosclerotic cardiovascular disease (ASCVD), heart failure with preserved ejection fraction (HFpEF), and chronic kidney disease (CKD), reflecting its broad cardiometabolic benefit profile beyond glycemic control.
